Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,584.71 -167.98 (-0.24%) CMC Crypto 200
1,505.86 +17.32 (+1.16%)
4D Molecular Therapeutics, Inc. (FDMT)
After hours:
| Previous close | 26.00 |
| Open | 25.06 |
| Bid | 25.13 x 200 |
| Ask | 25.23 x 200 |
| Day's range | 24.73 - 25.95 |
| 52-week range | 9.44 - 36.25 |
| Volume | |
| Avg. volume | 622,358 |
| Market cap | 1.3B |
| Beta (5Y monthly) | 2.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3 expected by Q1 2025Interim 24-week landmark analysis from PRISM Phase 2 Population Extension cohort evaluating 4D-150 in broader wet AMD population expected to be presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting on July 17-20, 2024Interim clinical data from Ph
- GlobeNewswire
4DMT to Participate in Upcoming Investor Conference
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at an upcoming investor conference in May. Members of the management team will also be available for one-on-one meetings. Bank of America Health Care Conference 2024 Presen
- GlobeNewswire
4DMT Announces Presentations at ARVO 2024 Annual Meeting
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the 2
